Arcutis Biotherapeutics, Inc.ARQTNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 0.78% |
| Q2 2025 | 10.89% |
| Q1 2025 | 21.15% |
| Q4 2024 | -25.75% |
| Q3 2024 | 1.05% |
| Q2 2024 | -16.61% |
| Q1 2024 | -2.67% |
| Q4 2023 | -9.38% |
| Q3 2023 | 4.03% |
| Q2 2023 | -28.65% |
| Q1 2023 | 4.33% |
| Q4 2022 | -51.42% |
| Q3 2022 | 82.52% |
| Q2 2022 | -5.95% |
| Q1 2022 | -22.71% |
| Q4 2021 | 29.44% |
| Q3 2021 | 31.98% |
| Q2 2021 | 42.23% |
| Q1 2021 | -20.98% |
| Q4 2020 | -16.40% |
| Q3 2020 | 9.11% |
| Q2 2020 | 19.17% |
| Q1 2020 | 134.10% |
| Q4 2019 | -12.88% |
| Q3 2019 | 71.17% |
| Q2 2019 | 16.30% |
| Q1 2019 | 16.01% |
| Q4 2018 | -24.49% |
| Q3 2018 | 156.93% |
| Q2 2018 | 0.00% |
| Q1 2018 | 0.00% |